Breaking News

Bayer Licenses Thrombosis Drug from Isis

Will assume clinical development and commercialization of ISIS-FXIRx

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bayer HealthCare has entered into an exclusive license agreement with Isis Pharmaceuticals, Inc. for ISIS-FXIRx, an antisense investigational drug in development for the prevention of thrombosis. Bayer will further develop and commercialize ISIS-FXIRx in areas of high unmet medical need.   Isis is eligible to receive an upfront payment and payment for the advancement of the program following a Phase II study in patients with compromised kidney function. Isis is also eligible to receive milestone...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters